Literature DB >> 21425417

Brief report: combined chemical treatment enables Oct4-induced reprogramming from mouse embryonic fibroblasts.

Xu Yuan1, Haifeng Wan, Xiaoyang Zhao, Saiyong Zhu, Qi Zhou, Sheng Ding.   

Abstract

It has been established that exogenous expression of four transcription factors (Oct4, Klf4, Sox2, and c-Myc) can reprogram mammalian somatic cells to pluripotent states. Further studies demonstrated that such induced pluripotent stem cells (iPSCs) could be generated with fewer exogenous transcription factors, facilitated by endogenous expression of reprogramming factors and/or synthetic small molecules. Here, we reported identification of a new small molecule, a protein arginine methyltransferase inhibitor AMI-5, which enabled Oct4-induced reprogramming of mouse embryonic fibroblasts in combination with transforming growth factor (TGF)-β inhibitor A-83-01. The Oct4-induced iPSCs were shown similar to mouse embryonic stem cells with respect to typical pluripotency criteria. More importantly, they were shown to give rise to liveborn pups through tetraploid complementation assays, demonstrating the high quality of full reprogramming induced by this condition. Furthermore, this study suggests that regulation of protein arginine methylation might be involved in the reprogramming process.
Copyright © 2011 AlphaMed Press.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21425417     DOI: 10.1002/stem.594

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  61 in total

Review 1.  Generation of pluripotent stem cells without the use of genetic material.

Authors:  Akon Higuchi; Qing-Dong Ling; S Suresh Kumar; Murugan A Munusamy; Abdullah A Alarfaj; Yung Chang; Shih-Hsuan Kao; Ke-Chen Lin; Han-Chow Wang; Akihiro Umezawa
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

Review 2.  A case of cellular alchemy: lineage reprogramming and its potential in regenerative medicine.

Authors:  Grace E Asuelime; Yanhong Shi
Journal:  J Mol Cell Biol       Date:  2012-02-27       Impact factor: 6.216

3.  HDAC inhibition promotes cardiogenesis and the survival of embryonic stem cells through proteasome-dependent pathway.

Authors:  Hong P Chen; Megan Denicola; Xin Qin; Yu Zhao; Ling Zhang; Xi L Long; Shougang Zhuang; Paul Y Liu; Ting C Zhao
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

Review 4.  Stem cell sources for vascular tissue engineering and regeneration.

Authors:  Vivek K Bajpai; Stelios T Andreadis
Journal:  Tissue Eng Part B Rev       Date:  2012-07-03       Impact factor: 6.389

Review 5.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

Review 6.  Toward pluripotency by reprogramming: mechanisms and application.

Authors:  Tao Wang; Stephen T Warren; Peng Jin
Journal:  Protein Cell       Date:  2013-11       Impact factor: 14.870

Review 7.  Chemical approaches to stem cell biology and therapeutics.

Authors:  Wenlin Li; Ke Li; Wanguo Wei; Sheng Ding
Journal:  Cell Stem Cell       Date:  2013-09-05       Impact factor: 24.633

8.  Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics.

Authors:  Jiekai Chen; Jing Liu; You Chen; Jiaqi Yang; Jing Chen; He Liu; Xiangjie Zhao; Kunlun Mo; Hong Song; Lin Guo; Shilong Chu; Deping Wang; Ke Ding; Duanqing Pei
Journal:  Cell Res       Date:  2011-03-29       Impact factor: 25.617

Review 9.  SWI/SNF chromatin remodeling complex: a new cofactor in reprogramming.

Authors:  Ling He; Huan Liu; Liling Tang
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

Review 10.  Regenerative medicine in Alzheimer's disease.

Authors:  Kevin M Felsenstein; Kate M Candelario; Dennis A Steindler; David R Borchelt
Journal:  Transl Res       Date:  2013-11-08       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.